ZHAOKE OPHTH-B - VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AND SUPPLY AGREEMENT WITH PT. ERELA TO COMMERCIALIZE CsA OPHTHALMIC GEL IN INDONESIA

Limited (the "Company") on a voluntary basis.

The Board of the Company is pleased to announce that the Company has entered into

a distribution and supply agreement with a reputable and well-established Indonesian pharmaceutical company PT. Erlangga Edi Laboratories ("PT. Erela"), for the commercialization of CsA Ophthalmic Gel, an innovative drug for the treatment of moderate- to-severe dry eye disease ("DED"), in Indonesia.

Under the terms of the agreement, the Company grants PT. Erela exclusive rights to register, import, promote, distribute, market, and sell CsA Ophthalmic Gel in Indonesia. The Company will receive an upfront payment and is eligible to receive additional milestone payments based on specific achievements.

ABOUT CsA OPHTHALMIC GEL

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by the Company

in China for the treatment of moderate to severe DED. Unlike Restasis®, an emulsion formulation, Cyclosporine ophthalmic gel is a patented hydrogel featuring excellent mucoadhesion and prolonged corneal residence time. Adopting nanomicelle formulation technology, it enhances corneal penetration and boosts the bioavailability of cyclosporine

A. In fact, the previous phase II study results suggested that 0.05% CsA Ophthalmic Gel (q.d.), applied once daily at night, had efficacy and safety profiles at least similar to those of Restasis® (0.05% CsA, b.i.d.) which is applied twice daily. This effectively eliminates the need for daytime administration and the associated discomfort and inconvenience. In addition, the results of the previous phase III study (COSMO) conducted by the Company indicate that

– 1 –

the onset of action for CsA Ophthalmic Gel can start in as early as two weeks. As a result of

once daily application and a rapid onset of action, the Company expects its CsA Ophthalmic Gel to significantly improve patients' compliance and quality of life.

ABOUT PT. ERLANGGA EDI LABORATORIES

PT Erela is a leading Indonesian pharmaceutical company established in 1965 by Drs. Edi Handojo and Dra. Kusumawati Handojo. The company began its operations on Jalan Erlangga in Semarang, Indonesia.

PT Erela is engaged in the development and manufacturing of pharmaceuticals, traditional medicines, health supplements, and health beverages, with a diversified portfolio of more than 150 SKUs. The company serves both domestic and international market needs.

With an extensive commercial and distribution network, PT Erela reaches more than 10,000 pharmacy outlets and major hospital chains across Indonesia. This broad market access, combined with strong manufacturing and regulatory capabilities, positions the company as a reliable partner for pharmaceutical companies seeking to expand their presence in Indonesia

and the broader regional market.

In addition to its proprietary product portfolio, PT Erela provides professional toll manufacturing services for pharmaceutical enterprises. Leveraging its technical expertise, scalable production capacity, and regulatory compliance capabilities, the company offers

comprehensive manufacturing support and strategic partnership opportunities for industry players across the pharmaceutical sector. More on www.erela.co.id.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing

of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop, or commercialize CsA Ophthalmic Gel successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Zhaoke Ophthalmology Limited Dr. Li Xiaoyi Chairman

Hong Kong, June 5, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and

Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.

– 2 –